Celularity Gains FDA Orphan Drug Status on Strength of Placental Stem Cell Trials

On Tuesday, Celularity received Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) for its off-the-shelf natural killer cell therapy for malignant gliomas.